Eupraxia Pharmaceuticals Drives Pipeline Expansion with $89 Million in Cash and Positive RESOLVE Trial Results -( $EPRX $IBB $XBI )

Eupraxia Pharmaceuticals (EPRX) delivered an impressive third quarter for 2025, underpinned by breakthrough clinical data, robust financial positioning, and a clearer trajectory toward commercial success. The company’s RESOLVE trial in eosinophilic esophagitis (EoE) demonstrated sustained clinical remission and long-lasting improvements in tissue health after a single treatment—results that highlight the significant potential of Eupraxia’s proprietary EP-104GI therapy.

Strong Clinical Momentum

The RESOLVE trial’s 52-week findings showed that two-thirds of patients in the highest-dose cohort maintained clinical remission, with durable improvements in both symptoms and esophageal tissue health over a full year. These clinical gains, achieved without new safety concerns, position EP-104GI as a major innovation in EoE care with potential advantages over existing therapies’.

Eupraxia continues to enroll patients in the pivotal Phase 2b segment of RESOLVE, with top-line data expected in the third quarter of 2026. The strength of the 1-year clinical outcomes and the scalability of the trial signal exceptional potential for broad adoption.

Solid Financial Performance

Eupraxia secured $80.5 million in funding through a public offering completed in September 2025, resulting in a substantial cash runway projected to fund ongoing development and operations into the first half of 2028. This positions Eupraxia to expand its clinical programs and deliver key milestones without near-term financing concerns. The company’s strong fiscal management and continued support from leading life-sciences investors further reinforce confidence in its future trajectory.

Outlook – The Right Dose, the Right Place, the Right Amount of Time

Buoyed by clinical achievements and a substantial cash position, Eupraxia Pharmaceuticals (EPRX) is on track to deliver further value for patients and shareholders through 2026 and beyond. The latest data showcase the company’s leadership with its DiffusphereTM drug delivery technology for the treatment of eosinophilic esophagitis (EoE), EP-104IAR for knee osteoarthritis (OA), and its increasing relevance in addressing significant unmet needs in other inflammatory diseases, pain conditions and oncology indications..

Sources

1. https://www.biospace.com/press-releases/eupraxia-pharmaceuticals-reports-third-quarter-2025-financial-results
2. https://eupraxiapharma.com/wp-content/uploads/2025/08/2024_09_10_ISDE-2024-EoE-poster_FINAL.pdf
3. https://www.theglobeandmail.com/investing/markets/stocks/EPRX-T/pressreleases/35903214/eupraxia-pharmaceuticals-reports-third-quarter-2025-financial-results/
4. https://lifesciencesbc.ca/members/first-set-of-1-year-clinical-results-from-resolve-trial-in-eosinophilic-esophagitis-eoe-durable-and-sustained-symptom-tissue-responses-after-dosing-with-ep-104gi/
5. https://www.globenewswire.com/news-release/2025/09/02/3142594/0/en/First-Set-of-1-Year-Clinical-Results-from-RESOLVE-Trial-in-Eosinophilic-Esophagitis-EoE-Durable-and-Sustained-Symptom-Tissue-Responses-after-Dosing-with-EP-104GI.html
6. https://firstwordpharma.com/story/5956599
7. https://www.marketscreener.com/news/eupraxia-pharmaceuticals-brief-says-incurred-a-net-loss-of-us-6-4-million-in-q3-ce7d5cdfde8af42d